17 terminated. 17 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Terminated 17 |
| Phase 2 | 3 | Terminated 3 |
Follow poly ICLC: new trials by email Literature Review of poly ICLC trials Research Report on poly ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Neoantigen Peptide Vaccine, Poly ICLC, Blood for immune monitoring - Pancreas Cancer, Pancreatic Cancer | Phase 1 | Terminated | Washington University School of Medicine | 12 | 2020-02-13 | 2024-07-17 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Echopulse, Poly ICLC, Standard of Care PD-1 Therapy - Melanoma, Breast Cancer | Phase 1 | Terminated | Craig L Slingluff, Jr | 5 | 2019-11-21 | 2025-07-14 |
| Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma NeoVax, Nivolumab, Ipilimumab - Glioblastoma | Phase 1 | Terminated | Washington University School of Medicine | 3 | 2018-10-31 | 2021-10-27 |
| Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma Personalized tumor vaccine, Poly ICLC, Nivolumab - Follicular Lymphoma | Phase 1 | Terminated | Washington University School of Medicine | 4 | 2018-10-16 | 2023-08-14 |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma NEO-PV-01, Nivolumab, Adjuvant - Metastatic Melanoma | Phase 1 | Terminated | BioNTech US Inc. | 22 | 2018-10-08 | 2020-09-03 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Oregovomab, Poly ICLC - Cancer of Ovary, Neoplasms, Ovarian | Phase 1 | Terminated | CanariaBio Inc. | 10 | 2017-05-30 | 2020-12-22 |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) IMA950, poly-ICLC, Varlilumab - Glioma, Malignant Glioma | Phase 1 | Terminated | Nicholas Butowski | 14 | 2017-04-03 | 2024-06-14 |
| Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma Personalized peptide vaccine, Poly-ICLC, Temozolomide - Glioblastoma Multiforme, Astrocytoma, Grade IV | Phase 1 | Terminated | Washington University School of Medicine | 1 | 2015-12-03 | 2017-11-17 |
| Autologous OC-L Vaccine and Ovarian Cancer OC-L, Montanide, poly-ICLC (Hiltonol), - Primary Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Terminated | Abramson Cancer Center at Penn Medicine | 3 | 2015-05-01 | 2020-04-24 |
| A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma Combination of varlilumab and ipilimumab, Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC - Unresectable Stage III or Stage IV Melanoma | Phase 1 / Phase 2 | Terminated | Celldex Therapeutics | 9 | 2015-04-01 | 2017-04-07 |
| Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Vaccine (autologous dendritic cells), Decitabine and Hiltonol - Gliomas, Medulloblastoma | Phase 1 / Phase 2 | Terminated | University of Louisville | 1 | 2015-04-01 | 2018-05-04 |
| Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma Romidepsin, Poly ICLC, Focal lesional radiation - Cutaneous T-cell Lymphoma | Phase 1 | Terminated | NYU Langone Health | 3 | 2014-03-01 | 2018-12-24 |
| NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide - Unresectable or Metastatic Melanoma | Phase 1 | Terminated | Ludwig Institute for Cancer Research | 8 | 2014-01-24 | 2022-10-12 |
| Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells Poly ICLC, leukapheresis - Melanoma | Phase 1 | Terminated | Medical University of South Carolina | 1 | 2012-10-01 | 2015-10-02 |
| Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer poly-ICLC, 9 Peptides from Her-2/neu, CEA, & CTA, Peptide-tet - Breast Cancer | Phase 1 | Terminated | Craig L Slingluff, Jr | 11 | 2012-07-01 | 2020-05-08 |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Poly-ICLC - B Cell Lymphoma, T Cell Lymphoma | Phase 1 | Terminated | Nevada Cancer Institute | 3 | 2009-04-01 | 2011-07-20 |
Melanoma (5) · Ovarian Neoplasms (3) · Breast Neoplasms (2) · Fallopian Tube Neoplasms (2) · Glioblastoma (2) · Glioma (2) · Lymphoma, Follicular (2) · Astrocytoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1)
Washington University School of Medicine (4) · Craig L Slingluff, Jr (2) · Abramson Cancer Center at Penn Medicine (1) · BioNTech US Inc. (1) · CanariaBio Inc. (1) · Celldex Therapeutics (1) · Ludwig Institute for Cancer Research (1) · Medical University of South Carolina (1) · NYU Langone Health (1) · National Cancer Institute (NCI) (1) · Nevada Cancer Institute (1) · Nicholas Butowski (1) · University of Louisville (1)
United States (17) · Australia (1)
Catherine Diefenbach, MD (1) · Christopher Nicodemus, MD FACP (1) · Craig L Slingluff, MD (1) · Delva Deauna-Limayo, MD (1) · Gavin Dunn, M.D., Ph.D. (1) · Hassane M Zarour, MD (1) · Hideho Okada, MD, PhD (1) · Jonathan Cebon, MBBS, FRACP, PhD (1) · Keisuke Shirai, MD (1) · Kenneth G Lucas, MD (1) · Kunle Odunsi (1) · Lynn Dengel, MD, MSc (1) · Mark DeMario, MD (1) · Michael A Postow, MD (1) · Nancy Bartlett, M.D. (1)
PMID 29157306, PMID 32819975, PMID 34171339, PMID 38713894
P30CA016056 (1), P50CA196510 (1), R21CA233856 (1)